Sign In
Buy VERV
$11.13
+0 (+0%)
At Close: Oct 24, 2025
Eli Lilly to acquire gene-editing therapy developer Verve Therapeutics for up to $1.3 billion, companies say
06:54am, Tuesday, 17'th Jun 2025
Eli Lilly will acquire Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday.
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
06:45am, Tuesday, 17'th Jun 2025
Verve's leading programs aim to deliver lifelong cardiovascular risk reduction with a single dose by targeting genes strongly linked to cardiovascular disease Lilly's established capabilities in cardi
Eli Lilly Close to $1.3 Billion Bid for Biotech, Says Report. Verve Therapeutics Stock Soars 80%.
05:33am, Tuesday, 17'th Jun 2025
A report said the two pharmaceutical companies are in advance talks.
Eli Lilly lining up $1.3bn swoop for cholesterol specialist Verve
04:04am, Tuesday, 17'th Jun 2025
Eli Lilly and Co (NYSE:LLY) is in advanced discussions to acquire Verve Therapeutics in a deal worth up to $1.3 billion, according to the Financial Times. The proposed terms include a nearly $1 billio
Eli Lilly nears $1.3 billion deal for gene-editing biotech Verve Therapeutics, FT reports
07:49pm, Monday, 16'th Jun 2025
Eli Lilly is in advanced talks to acquire gene editing startup Verve Therapeutics for up to $1.3 billion, the Financial Times reported on Monday, citing people familiar with the matter.
What Makes Verve Therapeutics (VERV) a New Buy Stock
01:01pm, Friday, 13'th Jun 2025
Verve Therapeutics (VERV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average
10:32am, Friday, 06'th Jun 2025
From a technical perspective, Verve Therapeutics (VERV) is looking like an interesting pick, as it just reached a key level of support. VERV recently overtook the 200-day moving average, and this sugg
Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?
11:02am, Thursday, 05'th Jun 2025
The consensus price target hints at a 367.9% upside potential for Verve Therapeutics (VERV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Monday, 02'nd Jun 2025
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on May 30, 2025, the
Verve Therapeutics to Participate in Upcoming Investor Conferences
07:00am, Wednesday, 28'th May 2025
BOSTON , May 28, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that management will part
3 Top Genomics Stocks to Add to Your Portfolio in 2025
10:05am, Wednesday, 21'st May 2025
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
I Missed The Quantum Rally - I Won't Miss The Next One
05:47am, Tuesday, 20'th May 2025
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, progra
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
09:16am, Wednesday, 14'th May 2025
Verve Therapeutics (VERV) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.71. This compares to loss of $0.59 per share a year ago.
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2025 Financial Results
07:00am, Wednesday, 14'th May 2025
Reported positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 demonstrating dose-dependent decreases in blood LDL-C and PCSK9
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 02'nd May 2025
BOSTON , May 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on April 30, 2025, t
